NCT01372826

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

An Open-Label, Parallel-Group, Phase I Study to Compare the Pharmacokinetics of NKTR-118 Following a Single Oral Dose in Subjects With Renal Impairment and Subjects With Normal Renal Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This study will be assessing the pharmacokinetics of NKTR-118 in subjects with renal impairment compared to that in subjects with normal renal function.

Conditions

• Renal Impairment

Interventions

Type	Name	Description
DRUG	NKTR118 Group1	Oral dose, 25 mg
DRUG	NKTR118 Group 2	Oral dose, 25 mg
DRUG	NKTR118 Group3	Oral dose, 25 mg
DRUG	NKTR118	Oral dose, 25 mg

Timeline

• Start date: 2011-06-01
• Primary completion: 2011-10-01
• Completion: 2011-11-01
• First posted: 2011-06-14
• Last updated: 2014-10-15

Locations

3 sites across 1 country: United States